1Director Medical Education and Professor, Pulmonary Medicine, Era’s Lucknow Medical College and Hospital, Era University Lucknow, India
2Head-Growth and Scientific Support, Haystack Analytics Pvt Ltd, Society for Innovation and Entrepreneurship, Indian Institute of Technology-Mumbai, India
Keywords: Tuberculosis; Whole Genome Sequencing; Multi-Drug Resistant TB; End TB
TB: Tuberculosis; WGS: Whole Genome Sequencing; WHO: World Health Organization; MDR-TB: Multidrug Resistant TB; XDR-TB: Extremely Drug-Resistant; PMDT: Programmatic Management of Drug-Resistant TB; DST: Drug-Sensitivity Test; CDST: Culture-Drug Sensitivity; RR: Rifampicin Resistance; RRDR: Rifampicin Resistance Defining Region; NGS: Next Generation Sequencing; PZA: Pyrazinamide; INH: Isoniazid; RIF: Rifampicin; MIC: Minimum Inhibitory Concentration; MGIT: Mycobacterial Growth Indicator Tube; TA: Turn-Around-Time<
Tuberculosis (TB) affects millions every year, causing great morbidity and mortality worldwide (approximately 1.4 million lives in 2021) . Despite being preventable and curable, TB still remains a major challenge to public health, with a large number of patients failing to respond to standard treatment. TB dramatically affects the quality-of-life of the patients, and also raises many socio-economic issues especially in medium- and high-burden regions like India, Pakistan, China, Indonesia.
Rajendra Prasad and Aparna Bhanushali. “TB-Whole Genome Sequencing Bridging the Diagnostic Gaps for Effective Treatment”. EC Microbiology 19.6 (2023): 01-03.
© 2023 Rajendra Prasad and Aparna Bhanushali. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Open Access by ECronicon is
licensed under a Creative Commons Attribution
4.0 International License
Based on a work at www.ecronicon.net